The Player of Success: CRISPR Therapeutics AG (CRSP)
Developed jointly by Vertex Pharmaceuticals Incorporated (VRTX) and CRISPR Therapeutics AG (CRSP), CTX001 has received Priority Medicines (PRIME) status from the European Medicines Agency (EMA). It is now clear that the European Medicines Agency will assign PRIME status to CTX001 to treat transfusion-dependent beta-thalassemia. Before this treatment receiving priority status, it was used to treat […]
